Document is current
Any future updates will be listed below
-
Authors
Asleh, Karama https://orcid.org/0000-0002-2873-7253
Negri, Gian Luca https://orcid.org/0000-0001-7722-8888
Spencer Miko, Sandra E. https://orcid.org/0000-0001-6446-1584
Colborne, Shane
Hughes, Christopher S. https://orcid.org/0000-0002-6980-4459
Wang, Xiu Q.
Gao, Dongxia
Gilks, C. Blake
Chia, Stephen K. L.
Nielsen, Torsten O. https://orcid.org/0000-0003-3769-2517
Morin, Gregg B. https://orcid.org/0000-0001-8949-4374
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research
Canadian Cancer Society Research Institute (705463, 319465)
- License Information
-
More Information
Article History
Received: 19 March 2021
Accepted: 24 January 2022
First Online: 16 February 2022
Competing interests
: S.K.L.C. reports receiving consulting fees from Novartis Pharma, Pfizer, Hoffman LaRoche, Merck, AstraZeneca, Eli Lilly. T.O.N. played a role in the development of the PAM50 gene expression classifier, which has been licensed to Veracyte Technologies. The other authors declare no competing interests.
